Level-1 Data From the REDUCE Study and the PCPT Data

    October 2015 in “ Prostate Cancer
    Goutham Vemana, Gerald L. Andriole
    TLDR Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
    The document discussed two major studies evaluating the impact of 5-alpha-reductase inhibitors on prostate cancer risk. The Prostate Cancer Prevention Trial focused on men with low baseline PSA levels and found that finasteride significantly reduced the risk of prostate cancer detection, although it was associated with an increased diagnosis of higher-grade disease. The REDUCE trial examined the effects of dutasteride in men with elevated PSA levels, showing a significant reduction in prostate cancer risk without a statistical increase in higher-risk disease compared to placebo.
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    6 / 1000+ results